Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEPHALON/TAP PROSTATE DISEASE DRUG DEVELOPMENT AGREEMENT

Executive Summary

CEPHALON/TAP PROSTATE DISEASE DRUG DEVELOPMENT AGREEMENT is based on the neuroscience firm's receptor tyrosine kinase (RTK) effector program. Under the agreement announced May 17, Takeda- Abbott Pharmaceuticals will provide Cephalon with $5 mil. in R&D payments for research conducted in 1994, with subsequent payments to be determined annually. TAP also will take an equity stake in Cephalon of $14.4 mil., representing the purchase of 1.2 mil. shares, or 6.8% of the company.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel